Lantern Pharma Inc (LTRN)

$4.10 +0.29 (7.61%)
Market Cap 41.36M
Revenue (ttm) 0.00
Net Income (ttm) -20.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 718,500
Avg Vol 302,678
Day's Range N/A - N/A
Shares Out 10.80M
Stochastic %K 10%
Beta 1.47
Analysts Strong Sell
Price Target $25.50

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 277 1136
Address:
1920 McKinney Avenue, 7th Floor, Dallas, United States
NetworkNewsWire
NetworkNewsWire Sep. 16 at 7:59 PM
AINewsBreaks – $LTRN Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity https://ibn.fm/I0PxM
0 · Reply
DarthVestor
DarthVestor Sep. 16 at 7:34 PM
$LTRN why isn’t this pos up like 250%???
0 · Reply
BiotechBonesaw
BiotechBonesaw Sep. 16 at 3:14 PM
$LTRN nice win on your phase 1A 💪
0 · Reply
LVORA
LVORA Sep. 16 at 1:55 PM
$LTRN
0 · Reply
bkfViking123
bkfViking123 Sep. 16 at 1:19 PM
$LTRN has a future .... holding some ... low share count ... big price target.
0 · Reply
PinTheInvestor
PinTheInvestor Sep. 16 at 1:15 PM
$LTRN In for a bit sub-4. Not sure that this safety/tolerability/limited-efficacy news is enough to blow the top off, but at least should change momentum/get some good press.
0 · Reply
deerix
deerix Sep. 16 at 12:57 PM
$LTRN Grabbed some here
0 · Reply
DonCorleone77
DonCorleone77 Sep. 16 at 12:54 PM
$LTRN Lantern Pharma announces LP-184 trial met all primary endpoints
0 · Reply
dbr_island
dbr_island Sep. 16 at 12:53 PM
$LTRN watching….. LOADING HBIO on that news 🚢📦📦📦📦📦🚨
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 16 at 12:46 PM
$LTRN ​​Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
0 · Reply
Latest News on LTRN
Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Sep 16, 2025, 8:29 AM EDT - 11 hours ago

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Sep 10, 2025, 8:00 AM EDT - 6 days ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Sep 3, 2025, 9:44 AM EDT - 13 days ago

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Aug 13, 2025, 4:30 PM EDT - 4 weeks ago

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 6, 2025, 8:30 AM EDT - 5 weeks ago

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Aug 4, 2025, 8:55 AM EDT - 6 weeks ago

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Jul 28, 2025, 8:00 AM EDT - 7 weeks ago

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Jul 23, 2025, 7:56 AM EDT - 7 weeks ago

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Jul 21, 2025, 8:20 AM EDT - 2 months ago

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jul 15, 2025, 9:40 AM EDT - 2 months ago

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Jun 16, 2025, 8:30 AM EDT - 3 months ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 29, 2025, 8:30 AM EDT - 3 months ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

May 15, 2025, 3:04 PM EDT - 4 months ago

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 15, 2025, 8:45 AM EDT - 4 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 12, 2025, 9:00 AM EDT - 4 months ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 8, 2025, 8:30 AM EDT - 4 months ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

May 5, 2025, 8:55 AM EDT - 4 months ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:35 PM EDT - 6 months ago

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 6 months ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 6 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Feb 19, 2025, 8:00 AM EST - 7 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Jan 27, 2025, 7:55 AM EST - 8 months ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 9, 2024, 8:15 AM EST - 10 months ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Dec 3, 2024, 8:00 AM EST - 10 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 26, 2024, 8:45 AM EST - 10 months ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 19, 2024, 8:00 AM EST - 10 months ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:23 PM EST - 11 months ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:05 PM EST - 11 months ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Nov 5, 2024, 8:00 AM EST - 11 months ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 31, 2024, 8:00 AM EDT - 11 months ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 23, 2024, 8:45 AM EDT - 11 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 21, 2024, 8:00 AM EDT - 11 months ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Oct 15, 2024, 9:07 AM EDT - 1 year ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 4:01 AM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 7, 2024, 9:31 AM EDT - 1 year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 9, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 6, 2024, 3:00 AM EDT - 1 year ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

May 2, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Apr 22, 2024, 8:12 AM EDT - 1 year ago

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 11:14 PM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 18, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

NetworkNewsWire
NetworkNewsWire Sep. 16 at 7:59 PM
AINewsBreaks – $LTRN Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity https://ibn.fm/I0PxM
0 · Reply
DarthVestor
DarthVestor Sep. 16 at 7:34 PM
$LTRN why isn’t this pos up like 250%???
0 · Reply
BiotechBonesaw
BiotechBonesaw Sep. 16 at 3:14 PM
$LTRN nice win on your phase 1A 💪
0 · Reply
LVORA
LVORA Sep. 16 at 1:55 PM
$LTRN
0 · Reply
bkfViking123
bkfViking123 Sep. 16 at 1:19 PM
$LTRN has a future .... holding some ... low share count ... big price target.
0 · Reply
PinTheInvestor
PinTheInvestor Sep. 16 at 1:15 PM
$LTRN In for a bit sub-4. Not sure that this safety/tolerability/limited-efficacy news is enough to blow the top off, but at least should change momentum/get some good press.
0 · Reply
deerix
deerix Sep. 16 at 12:57 PM
$LTRN Grabbed some here
0 · Reply
DonCorleone77
DonCorleone77 Sep. 16 at 12:54 PM
$LTRN Lantern Pharma announces LP-184 trial met all primary endpoints
0 · Reply
dbr_island
dbr_island Sep. 16 at 12:53 PM
$LTRN watching….. LOADING HBIO on that news 🚢📦📦📦📦📦🚨
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 16 at 12:46 PM
$LTRN ​​Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
0 · Reply
TA_Kongen
TA_Kongen Sep. 16 at 12:42 PM
$LTRN Res 4.50. Kinda weak imo.
0 · Reply
TwongStocks
TwongStocks Sep. 16 at 12:39 PM
$LTRN Unhalts at 8:45am ET
0 · Reply
TA_Kongen
TA_Kongen Sep. 16 at 12:34 PM
$APVO $LTRN Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors Strong bio news this am. Watching. LTRN unhalt 8.45
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 16 at 12:30 PM
$LTRN news is just out here Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors "LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies." Its halted pending news, the unhalt will be released shortly.
1 · Reply
DARKP00L
DARKP00L Sep. 16 at 12:26 PM
$LTRN 08:25 on Sep. 16 2025 Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending #tradeideas
0 · Reply
DonCorleone77
DonCorleone77 Sep. 16 at 12:26 PM
$LTRN Lantern Pharma trading halted, news pending
1 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 10 at 2:42 PM
BioMedNewsBreaks — $LTRN CEO Panna Sharma Featured on IBN’s BioMedWire Podcast https://ibn.fm/ITg2o
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 3 at 7:56 PM
BioMedNewsBreaks — $LTRN Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial https://ibn.fm/KDpha
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 8:07 AM
$LTRN Really good write-up that perfectly summarizes LTRN's present situation. So if you want to bring your LTRN knowledge up to date or just discover LTRN, this is required reading. https://beyondspx.com/quote/LTRN/lantern-pharma-s-ai-engine-accelerating-oncology-s-future-nasdaq-ltrn#analysis
0 · Reply
Daddy044
Daddy044 Aug. 31 at 12:49 AM
$LTRN This is an incredibly underrated stock. Doing some work on overlooked biotech. Data, AI, lots of positive news forthcoming. Hit $6 a few weeks ago and now a pullback to $4. I will be a buyer on Tuesday.
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 28 at 7:12 PM
MissionIRNewsBreaks – $LTRN Advances Predictive Power in Cancer Drug Development https://ibn.fm/5maVc
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 28 at 12:04 PM
$LTRN interesting
0 · Reply